TipRanks
Advertisement
Advertisement

BIVI Stock Latest News

BioVie’s NE3107 Long COVID Trial Completion: What Investors Should Watch Next
Company AnnouncementsBioVie’s NE3107 Long COVID Trial Completion: What Investors Should Watch Next
22d ago
BIVI
BioVie announces topline results from ADDRESS-LC trial
PremiumThe Fly
BioVie announces topline results from ADDRESS-LC trial
29d ago
BIVI
BioVie completes treatment phase of ADDRESS-LC trial
PremiumThe Fly
BioVie completes treatment phase of ADDRESS-LC trial
1M ago
BIVI
BioVie says Phase 2 SUNRISE-PD trial of bezisterim met primary endpoint
PremiumThe Fly
BioVie says Phase 2 SUNRISE-PD trial of bezisterim met primary endpoint
2M ago
BIVI
BioVie Announces Positive Phase 2 Parkinson’s Trial Results
PremiumCompany Announcements
BioVie Announces Positive Phase 2 Parkinson’s Trial Results
2M ago
8K
BIVI
BioVie files to sell Class A common stock, warrants, no amount given
PremiumThe FlyBioVie files to sell Class A common stock, warrants, no amount given
3M ago
BIVI
BioVie files $300M mixed securities shelf
Premium
The Fly
BioVie files $300M mixed securities shelf
4M ago
BIVI
BioVie announces full enrollment of ADDRESS-LC trial of bezisterim
Premium
The Fly
BioVie announces full enrollment of ADDRESS-LC trial of bezisterim
5M ago
BIVI
BioVie completes SUNRISE-PD trial in early-stage Parkinson’s disease
PremiumThe Fly
BioVie completes SUNRISE-PD trial in early-stage Parkinson’s disease
5M ago
BIVI
BioVie completes enrollment in Phase 2 SUNRISE-PD trial
PremiumThe Fly
BioVie completes enrollment in Phase 2 SUNRISE-PD trial
9M ago
BIVI
BioVie Stockholders Approve Key Proposals at Annual Meeting
PremiumCompany Announcements
BioVie Stockholders Approve Key Proposals at Annual Meeting
11M ago
8K
BIVI
BioVie Inc.’s NE3107: A Promising Study for Long COVID Relief
PremiumCompany Announcements
BioVie Inc.’s NE3107: A Promising Study for Long COVID Relief
12M ago
BIVI
BioVie Inc.’s NE3107 Study: A New Hope for Early Parkinson’s Treatment
PremiumCompany AnnouncementsBioVie Inc.’s NE3107 Study: A New Hope for Early Parkinson’s Treatment
12M ago
BIVI
BioVie price target adjusted to $12 from $6 at Brookline
Premium
The Fly
BioVie price target adjusted to $12 from $6 at Brookline
1y ago
BIVI
BioVie Completes $10.4 Million Public Offering
Premium
Company Announcements
BioVie Completes $10.4 Million Public Offering
1y ago
8K
BIVI
Why Is BioVie Stock (BIVI) Down 50% Today?
PremiumMarket News
Why Is BioVie Stock (BIVI) Down 50% Today?
1y ago
BIVI
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
PremiumMarket News
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
1y ago
LLY
MRM
BioVie 6M share Secondary priced at $2.00
PremiumThe Fly
BioVie 6M share Secondary priced at $2.00
1y ago
BIVI
BioVie presents data on Bezisterim at WCAG-2025
PremiumThe Fly
BioVie presents data on Bezisterim at WCAG-2025
1y ago
BIVI
BioVie Expands Board Amid Drug Development Momentum
PremiumCompany AnnouncementsBioVie Expands Board Amid Drug Development Momentum
1y ago
8K
BIVI
BioVie appoints Amy Chappell, Kameel Farag to board of directors
Premium
The Fly
BioVie appoints Amy Chappell, Kameel Farag to board of directors
1y ago
BIVI
BioVie reports results from bezisterim Phase 3 NM101 study
Premium
The Fly
BioVie reports results from bezisterim Phase 3 NM101 study
1y ago
BIVI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >